** Shares of drug developer Candel Therapeutics CADL.O more than double to $10.17 premarket
** Company says its cancer therapy CAN-2409 met the main goal of a late-stage trial in patients with a type of prostate cancer
** CAN-2409, along with radiation therapy, showed a statistically significant improvement in disease-free survival vs radiation therapy alone - CADL
** Disease-free survival is the length of time after treatment that a patient survives without any signs or symptoms of the disease
** Up to last close, stock up 213.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。